Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. (2nd January 2022)

• Record Type: Journal Article
• Authors: Kong, Christina L.; Kelly, Nicole K.; Sundararajan, Miel; Rathinam, S.R.; Gonzales, John A.; Thundikandy, Radhika; Vedhanayaki, Rajesh; Kanakath, Anuradha; Murugan, Bala; Doan, Thuy; Goldstein, Debra; Al-Dhibi, Hassan A.; Acharya, Nisha R.
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 1(2022)
• Page Start: 198
• Page End: 202
• Publication Date: 2022-01-02
• Subjects: CD4 -- mycophenolate mofetil -- methotrexate -- antimetabolite -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2020.1774906
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: Sub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX). Methods: Patients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression. Results: There was no significant difference in ∆CD4 between MMF and MTX at 6 months (−31.7 cells/μL for MMF compared to MTX; 95% CI: −358.2 to 294.8, P = .85) and 12 months (−78.3 cells/μL for MMF compared to MTX; 95% CI: −468.0 to 311.3; P = .69). Conclusion: There was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients. ClinicalTrials.gov Identifier: NCT 01829295